What's Happening

You are here

[Issue No. 171] PSS E-Bulletin December 2020

In the second part of this series, we are honoured to share perspectives and experiences from two pharmacists – Ms Charlene Ng, who runs the Anticoagulation Clinic (ACC) and Ms Oh Jing Wen, who runs the Cardiac Pharmacist Clinic (CPC). Grace Chang, the lead for Ambulatory Clinics, also provided additional input.

2020 has passed by in a flash and we adapted and embraced the new normal in the Covid-19 times. Many congresses and conferences were converted to the online format and attending them no longer require juggling between the logistics on booking flights, accommodation and planning leave from work.

PSS Intermediate and Long-Term Care (ILTC) Pharmacists Workgroup had the privilege and honour of presenting a poster at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, 12-15 Nov 2020, held online this year.

During the enthusiastic discussions on Coffee Chat and Straight Talk engagements with our Chief Pharmacist in the recent months, we’ve heard pharmacists from different sectors candidly share their concerns, especially on the future of pharmacy landscape.

Looking through the questions raised in Pigeon Hole and during the sessions, the following four broad categories of queries were frequently raised. As such, we have prepared a video and presentation to address the concerns on how to future proof yourself and pharmacy through the different initiatives under the National Pharmacy Strategy. Together as one Pharmacy family, we can work together to co-create the future of pharmacy!

The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and Panel of Infectious Diseases Experts, would like to inform healthcare professionals on the interim authorisation of Pfizer-BioNTech COVID-19 Vaccine for active immunisation to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals 16 years of age and over. HSA has also issued a Dear Healthcare Professional Letter (DHCPL) to highlight to healthcare professionals the requirements on the safety monitoring of COVID-19 vaccine(s) that has been authorised for use in Singapore.

In this issue, the HSA editorial team brings you safety updates on the use of montelukast and pirfenidone, sibutramine-induced AE characteristics due to adulterated health products, the voluntary withdrawal of Esmya TM Tablet 5mg in Singapore and a case study of Miller Fisher Syndrome in a patient. We would also like to remind healthcare professionals on vaccine AE reporting and to verify HLA-B*1502 status in new patients of Asian ancestry before starting carbamazepine.

This webinar will explain what Cardiac Contractility Modulation therapy is, how it works, and what you can expect in terms of outcomes when utilizing this treatment for NYHA Class III patients who remain symptomatic in spite of guideline directed medical therapy.